Screener
Assembly Biosciences ASMB Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Assembly Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211987
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $235,508 | $257,590 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities | ||
| Accounts payable | $1,129 | $1,171 |
| Accrued research and development expenses | 1,538 | 2,387 |
| Other accrued expenses | 2,664 | 7,749 |
| Deferred revenue from a related party | 29,076 | 36,904 |
| Operating lease liabilities - short-term | 590 | 569 |
Item 1. Financial Statements
FAQ
- What is Assembly Biosciences's accounts payable?
- Assembly Biosciences (ASMB) reported accounts payable of $1.13M in Q1 2026.
- How has Assembly Biosciences's accounts payable changed year-over-year?
- Assembly Biosciences's accounts payable increased by 29.0% year-over-year, from $875K to $1.13M.
- What is the long-term trend for Assembly Biosciences's accounts payable?
- Over 5 years (2020 to 2025), Assembly Biosciences's accounts payable has grown at a -23.9% compound annual growth rate (CAGR), from $4.6M to $1.17M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Assembly Biosciences's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude